Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer

被引：0
|
作者：
Xerxes Pundole
Natalia V. Zamora
Harish Siddhanamatha
Heather Lin
Jean Tayar
Leung Cheuk Hong
Liang Li
Maria E. Suarez-Almazor
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology
[2] Instituto de Rehabilitación Psicofísica,Sección Reumatología
[3] Augusta University Medical Center,Department of Data Integrity and Analytics
[4] The University of Texas MD Anderson Cancer Center,Department of Biostatistics
来源：
Clinical Rheumatology | 2020年 / 39卷
关键词：
Biologic; Cancer; DMARD; Rheumatoid arthritis; Tumor necrosis factor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：787 / 794
页数：7
相关论文
共 50 条
  • [1] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Pundole, Xerxes
    Zamora, Natalia V.
    Siddhanamatha, Harish
    Lin, Heather
    Tayar, Jean
    Hong, Leung Cheuk
    Li, Liang
    Suarez-Almazor, Maria E.
    CLINICAL RHEUMATOLOGY, 2020, 39 (03) : 787 - 794
  • [2] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [3] The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs
    Pombo-Suarez, Manuel
    Gomez-Reino, Juan
    PHARMACOLOGICAL RESEARCH, 2019, 148
  • [4] Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients
    Convertino, Irma
    Cazzato, Massimiliano
    Tillati, Silvia
    Giometto, Sabrina
    Gini, Rosa
    Valdiserra, Giulia
    Cappello, Emiliano
    Ferraro, Sara
    Bonaso, Marco
    Bartolini, Claudia C.
    Paoletti, Olga
    Lorenzoni, Valentina
    Filippi, Matteo
    Turchetti, Giuseppe
    Cristofano, Michele
    Blandizzi, Corrado
    Mosca, Marta
    Lucenteforte, Ersilia
    Tuccori, Marco
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 488 - 489
  • [5] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [6] RACIAL DISPARITIES IN UTILIZATION OF BIOLOGIC AND DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN A CALIFORNIA MEDICAID POPULATION WITH RHEUMATOID ARTHRITIS
    Nichol, M. B.
    Wu, J.
    Harker, J. O.
    Knight, T. K.
    Wong, A. L.
    VALUE IN HEALTH, 2011, 14 (03) : A132 - A132
  • [7] Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Agarwal, S.
    Zaman, T.
    Handa, R.
    SINGAPORE MEDICAL JOURNAL, 2009, 50 (07) : 686 - 692
  • [8] Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
    Hanaoka, Hironari
    Kikuchi, Jun
    Hiramoto, Kazuoto
    Saito, Shuntaro
    Kondo, Yasushi
    Kaneko, Yuko
    CLINICAL KIDNEY JOURNAL, 2022, 15 (07) : 1373 - 1378
  • [9] SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS ON THE TREATMENT WITH BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Hasegawa, E.
    Ito, S.
    Kurosawa, Y.
    Taniguchi, S.
    Kobayashi, D.
    Abe, A.
    Otani, H.
    Nakazono, K.
    Murasawa, A.
    Narita, I.
    Ishikawa, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 985 - 985
  • [10] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
12345